Wednesday, May 21, 2025

PostEra Expands AI Drug Discovery Deal with Pfizer to $610M

Related stories

Accenture, Dell & NVIDIA Accelerate Enterprise AI with AI Refinery

New AI solution helps organizations scale AI in private,...

Virtana Launches First Full-Stack AI Factory Monitoring

Unique new capabilities help enterprises tame AI infrastructure complexity,...

15Five Debuts Kona AI Manager Coach at 15Five Next

Kona provides tailored coaching and enablement to managers in...

Dell Revamps Data Centers with Software-Driven Infrastructure

Dell software-driven advancements automate the management and deployment of...

Deloitte to Integrate Zora AI™ With SAP Joule for Reasoning

The planned integration will allow Zora AI and SAP...
spot_imgspot_img

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced an expansion of their partnership with Pfizer. The parties will launch a new Antibody-Drug-Conjugate (ADC) collaboration while also expanding their existing $260M AI Lab collaboration, which itself was built upon a successful Generative Chemistry partnership.

The teams will leverage PostEra’s AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, to advance several programs. These new programs include small molecule therapeutics as well as ADCs, where PostEra will use Proton to optimize properties of payloads.

PostEra will receive an upfront payment of $12M and is eligible to receive additional milestone payments and tiered royalties on any approved products arising out of the collaboration.

Over the last 3 years, as part of the AI Lab, PostEra and Pfizer scientists have partnered closely to advance several small molecule programs. After Pfizer nominated the maximum number of programs, the teams have agreed to expand the collaboration to include additional targets with PostEra receiving additional upfront payment and eligibility for milestones and royalties.

Also Read: eClinical Solutions Partners with Snowflake to Streamline Life Sciences Data

“We’re pleased to significantly expand the use of PostEra’s Proton platform. This builds on peer-reviewed publications with Pfizer validating the real-world impact of AI-driven drug discovery in hitting preclinical milestones faster than anticipated,” said Alpha Lee, Chief Scientific Officer of PostEra. “This third partnership with our long-term collaborators at Pfizer underscores Proton’s depth and strength in making a meaningful impact on real-world drug discovery campaigns,” added Aaron Morris, CEO of PostEra.

PostEra is building a modern 21st century biopharma. We use Proton, our AI platform for medicinal chemistry, to accelerate the discovery of new medicines for patients. PostEra is advancing an internal pipeline while also advancing small molecule programs through partnerships with biopharma.

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img